Definium Therapeutics Inc. Common Shares vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 12.3× Definium Therapeutics Inc. Common Shares's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| DFTX | TAK | |
|---|---|---|
Market Cap | $4.71B | $58.16B |
Volume | 1,966,636 | 2,467,530 |
Sector | Health | Health |
52-Week High | $48.45 | $19.05 |
52-Week Low | $10.68 | $13.23 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.67B | $86.04B |
Dividend Yield | — | 3.36% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →